STOCK TITAN

Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will release its second quarter 2022 financial results and corporate updates on August 11, 2022. The presentation will be followed by a conference call at 8:30 a.m. EDT, accessible via phone or webcast. Affimed focuses on harnessing the innate immune system to fight cancer, featuring its proprietary ROCK® platform which creates innovative innate cell engager (ICE®) molecules. This approach positions Affimed as a pioneer in clinical-stage ICE® development.

Positive
  • Commitment to utilizing the innate immune system for cancer treatment.
  • Proprietary ROCK® platform enables innovative tumor-targeted therapies.
  • First clinical-stage ICE® developer, showcasing leadership in the field.
Negative
  • None.

HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time.

The conference call will be available via phone and webcast. To access the call, please dial +1 (866) 374-5140 for U.S. callers, or +1 (404) 400-0571 for international callers, and use PIN : 54780189# approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of the Company’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102


FAQ

When will Affimed N.V. release its Q2 2022 results?

Affimed N.V. will release its Q2 2022 results on August 11, 2022.

What time is the Affimed N.V. conference call scheduled?

The conference call is scheduled for 8:30 a.m. Eastern Daylight Time on August 11, 2022.

How can I access the Affimed N.V. conference call?

You can access the call by phone or through a webcast on Affimed's website.

What is the significance of the ROCK® platform for Affimed N.V.?

The ROCK® platform allows Affimed to develop targeted therapies that utilize the innate immune system to combat various cancers.

Affimed N.V.

NASDAQ:AFMD

AFMD Rankings

AFMD Latest News

AFMD Stock Data

20.82M
15.48M
6.01%
36.99%
6.27%
Biotechnology
Healthcare
Link
United States of America
Mannheim